In breast cancer, regulatory feedback loops between the IGF axis and the mTOR/PI3K/AKT pathway may limit the efficacy of mTOR inhibitor/endocrine therapy combinations due to compensatory IGF ligand-driven signalling [2, 10]. The gene discussed is MTOR; the disease is breast cancer.